Circio Holding ASA – Share capital increase registered

Summary by AI ^BETAClose X

Circio Holding ASA has registered a share capital increase of NOK 57,262.80 through the issuance of 95,438 new shares at NOK 0.60 each to Atlas Special Opportunities, LLC, settling compensation related to convertible bonds. Following this, the company's registered share capital is now NOK 164,776,746, comprising 274,627,910 shares with a nominal value of NOK 0.60 per share.

Disclaimer*

Oslo, 22 June 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (OSE: CRNA) (the “Company” or “Circio”) on 9 June 2026 regarding the board of directors resolving the issuance of new shares to Atlas Special Opportunities, LLC (“Atlas”) in connection with compensation by the Company to Atlas in relation to the conversion of convertible bonds in 2024 and 2025.

The issuance of the new shares increased the Company’s share capital by NOK 57,262.80, through the issuance of 95,438 shares at a subscription price of NOK 0.60 per share.

The share capital increase pertaining to the issuance of the new shares is now registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following the registration, the Company’s new registered share capital is NOK 164,776,746, divided into 274,627,910 shares, each with a nominal value of NOK 0.60.

This information is subject to the disclosure requirements pursuant to the Continuing Obligations and Section 5-12 of the Norwegian Securities Trading Act.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.